These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3317747)

  • 1. Characterization of a nontoxic monophosphoryl lipid A.
    Johnson AG; Tomai M; Solem L; Beck L; Ribi E
    Rev Infect Dis; 1987; 9 Suppl 5():S512-6. PubMed ID: 3317747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monophosphoryl lipid A and endotoxin tolerance.
    Hamilton-Davies C; Webb AR
    Crit Care Med; 1995 Oct; 23(10):1789-90. PubMed ID: 7587249
    [No Abstract]   [Full Text] [Related]  

  • 3. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.
    Casella CR; Mitchell TC
    Cell Mol Life Sci; 2008 Oct; 65(20):3231-40. PubMed ID: 18668203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice.
    Tomai MA; Solem LE; Johnson AG; Ribi E
    J Biol Response Mod; 1987 Apr; 6(2):99-107. PubMed ID: 3585413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immuno-Stimulatory Activity of Escherichia coli Mutants Producing Kdo2-Monophosphoryl-Lipid A or Kdo2-Pentaacyl-Monophosphoryl-Lipid A.
    Wang B; Han Y; Li Y; Li Y; Wang X
    PLoS One; 2015; 10(12):e0144714. PubMed ID: 26710252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the immunomodulating properties of two forms of monophosphoryl lipid A analogues.
    Johnson AG; Tomai MA; Chen YF; Odean M
    J Immunother (1991); 1991 Dec; 10(6):398-404. PubMed ID: 1768673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
    Mata-Haro V; Cekic C; Martin M; Chilton PM; Casella CR; Mitchell TC
    Science; 2007 Jun; 316(5831):1628-32. PubMed ID: 17569868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunobiological activities of synthetic lipid A analogs with low endotoxicity.
    Kotani S; Takada H; Takahashi I; Ogawa T; Tsujimoto M; Shimauchi H; Ikeda T; Okamura H; Tamura T; Harada K
    Infect Immun; 1986 Dec; 54(3):673-82. PubMed ID: 3781622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants.
    Alving CR
    Immunobiology; 1993 Apr; 187(3-5):430-46. PubMed ID: 8330907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid A-Mediated Bacterial-Host Chemical Ecology: Synthetic Research of Bacterial Lipid As and Their Development as Adjuvants.
    Shimoyama A; Fukase K
    Molecules; 2021 Oct; 26(20):. PubMed ID: 34684874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].
    Rietschel ET; Brade H
    Infection; 1987; 15(2):133-41. PubMed ID: 2439461
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid A and immunotherapy.
    Ribi E; Cantrell JL; Takayama K; Qureshi N; Peterson J; Ribi HO
    Rev Infect Dis; 1984; 6(4):567-72. PubMed ID: 6382555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid A precursors protect against endotoxin challenge.
    Proctor RA
    Adv Exp Med Biol; 1990; 256():641-52. PubMed ID: 2183568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nontoxic, idiotope vaccine against gram-negative bacterial infections.
    Su S; Ward MM; Apicella MA; Ward RE
    J Immunol; 1992 Jan; 148(1):234-8. PubMed ID: 1727868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lipopolysaccharides, endotoxins and O-antigens of gram-negative bacteria: chemical structure, biologic effect and serologic properties].
    Rietschel ET; Brade H
    Infection; 1987; 15 Suppl 2():S76-84. PubMed ID: 2440812
    [No Abstract]   [Full Text] [Related]  

  • 16. Endogenous production of cytotoxic factors in serum of BCG-primed mice by monophosphoryl lipid A, a detoxified form of endotoxin.
    Bennett JA; Peters JH; Chudacoff R; McKneally MF
    J Biol Response Mod; 1988 Feb; 7(1):65-76. PubMed ID: 3373236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary oxygen toxicity in rats: prevention by pyrogenic diphosphoryl lipid A and potentiation by nontoxic monophosphoryl lipid A and lipid X.
    Smith RM
    Res Commun Chem Pathol Pharmacol; 1988 Nov; 62(2):221-34. PubMed ID: 3075066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The adjuvant effect of bacterial endotoxin: its active component and action mechanism].
    Nakano M
    Nihon Rinsho; 1974 Aug; 32(8):2715-22. PubMed ID: 4612210
    [No Abstract]   [Full Text] [Related]  

  • 19. Separation and characterization of toxic and nontoxic forms of lipid A.
    Takayama K; Qureshi N; Ribi E; Cantrell JL
    Rev Infect Dis; 1984; 6(4):439-43. PubMed ID: 6474003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
    Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
    BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.